Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT03019536
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kurume, Japan
🇺🇸Bioclinica, The Villages, Florida, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Basal Insulin AnalogDrug: Insulin Analog Mid Mixture
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 814
- Registration Number
- NCT03018938
- Locations
- 🇨🇳
Ningbo First Hospital, Ningbo, Zhejiang, China
🇨🇳Peking University International Hospital, Beijing, China
🇨🇳Beijing Huaxin Hospital, Beijing, Beijing, China
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT03012334
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT03009162
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
🇨🇦CIUSSS de l'est-de-l'île-de-Montréal - installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
A Study of Ixekizumab in Participants With Plaque Psoriasis
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02993471
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Avail Clinical Research LLC, DeLand, Florida, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
A Study of LY3323795 in Healthy Participants
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT02989389
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 106
- Registration Number
- NCT02981342
- Locations
- 🇺🇸
Illinois CancerCare, Peoria, Illinois, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Sarah Cannon Cancer Center, Nashville, Tennessee, United States
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 318
- Registration Number
- NCT02973100
- Locations
- 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States
🇺🇸Marin Endocrine Associates, Greenbrae, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
A Study of LY3305677 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3305677Drug: Placebo
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT02972645
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 154
- Registration Number
- NCT02963766
- Locations
- 🇺🇸
ECU Pediatric Specialty Care, Greenville, North Carolina, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States